Global Genomics in Cancer Care Market - 2021-2028
|出版日期||內容資訊||英文 180 Pages
|癌症治療的基因學的全球市場(2021年∼2028年) Global Genomics in Cancer Care Market - 2021-2028|
|出版日期: 2021年05月27日||內容資訊: 英文 180 Pages||
The global genomics in cancer care market size was valued US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
Genomics plays a crucial role in precision medicine and drug development for cancer. Identifying Cancer-causing mutations is very crucial, and Genomics plays a vital role in achieving this. Genetic mutations do not have such a central role in all cancer diagnoses, but even if they don't, their presence or absence might change how each person's cancer is described.
At the Netherlands Cancer Institute, each person with metastatic cancer must use their cancer genome sequencing. Its database now includes genomic-sequencing data from around 5,000 people. For people with a cancer mutation that an achievable therapy can target, there is no question that cancer-genome sequencing directs to better outcomes and survival.
The genomics in cancer care market growth is driven by the increasing application in diagnostics, personalized medicine, and drug discovery & development. Factors such as rising incidence of cancer, increasing awareness about early disease diagnosis, growing geriatric population, and advancement in technology drive the market growth.
Incresing geriatric population and advancement in technology will drive the market growth
According to the Global Health and Aging report published by the World Health Organization, the number of people aged 65 years or greater is expected to increase from a predicted 524 million in 2010 to about 1.5 billion by 2050, with a significant percentage of increase in emerging economies. Primary chronic diseases such as cancer have had the most significant impact on the geriatric population, especially in high-income countries. Thus, the growing prevalence of diseases in the increasing geriatric population is expected to propel the growth of the genomic cancer care market in the forecast period.
Detection of cancer at an initial stage significantly raises the possibilities for survival. Creating awareness to promote early diagnosis and screening are the essential steps responsible for early detection of disease comprising breast, blood, colorectal, lung, and cervical, among others. Recognizing likely warning symptoms of cancer and taking active measures is necessary for early diagnosis. Greater appreciation of probable signs of the disease amongst physicians, nurses, and other healthcare providers and the general public would positively influence the survival rate and help increase the genomics in cancer care market demand.
The rising in cancer and biotechnological advancements related to cancer care
The rise in cancer and biotechnological advancements related to cancer care is a significant factor in propelling the market growth. According to Globocan 2020, an expected 19,292,789 new cancer cases were diagnosed worldwide, with approximately 9,958,133 deaths due to cancers. In addition, as per the International Agency for Research on Cancer, the proportion of cancer cases is expected to grow to 27.5 million new cases and 16.3 million deaths worldwide by 2040. The rising incidence of cancer cases is anticipated to drive the need for superior diagnostics and treatment options for cancers, which is supposed to boost the market. Also, the launch of new products and efficient strategic collaborations between key players is expected to drive the market. For instance, in Sep 2020, Thermo Oncamine Precision Assay and Fisher Scientific's Ion Torrent Genexus System were selected by the LC-SCRUM-Asia, a leading cancer genomic screening program, to develop precision medicine in Asia. Thus, because of the factors mentioned above, the genomic in the cancer care market is predicted to register significant growth over the forecast period globally.
High price associated with genomics devices will hamper the market growth
However, the high price associated with genomics devices may create restraints in the growth of genomics in the cancer care market in the forecast period..
COVID-19 Impact Analysis
Due to the COVID-19 pandemic, in May 2020, Genomics England partnered with the genomic consortium, directed by the University of Edinburgh. This partnership intended to identify and investigate the whole genome sequences of approximately 35,000 COVID-19 infected patients with symptoms varying from mild to severe. The Genomics England, the Department of Health and Social Care, and the National Institute for Health Research granted about GBP 28 million for the project. Illumina was involved in sequencing all 35,000 genomes. Hence, the genome sequencing segment is expected to grow during the COVID-19 pandemic in the forecast period.
By technology, the genomics in cancer care market is classified into genome sequencing, pcr, microarray, nucleic acid extraction and purification.
Genome Sequencing segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)
Developing technology related to genome sequencing is anticipated to fuel market growth. Next-Generation sequencing is a novel method having wide application in oncology. DNA sequencing and RNA sequencing helps in detecting and analyzing the modifiers, mutation analysis, and pharmacogenetics of biopsy.
According to the research article published in Trends in Cancer, 2019, DNA sequencing and other genomics have been harnessed to study the genetic aberrations of human cancers to obtain information that aids in increasing precision in assigning drugs to patients. For instance, the development of targeted treatments which include small molecule therapeutics targeting specific gene mutations, such as imatinib for c-KIT gene mutation in Chronic Myeloid Leukemia and Gastrointestinal Stromal Tumors. In Aug 2020, AncestryHealth, based on Next Generation Sequencing, was launched by Ancestry to help customers understand their health and risk factors. It is a vital tool to screen genes associated with breast cancer, colon cancer, and blood disorders. Hence, the growing investment in genome sequencing research and development activities, along with the novel product launches, is expected to aid in the healthy growth of the studied segment over the forecast period.
Also, in October 2019, GENOMIKA, the leading genetic testing laboratory in Brazil, reached an agreement with Veritas Intercontinental to incorporate the whole genome and exome sequencing in its portfolio, along with all the services associated with these tests in the field of preventive medicine and clinical genetics.
Furthermore, its advantages over other techniques are known to boost the growth of the studied segment. For instance, in August 2020, the FDA approved the first liquid biopsy companion diagnostic that leverages Next-generation sequencing (NGS) technology to guide cancer treatment. The Guardant360 CDx assay promotes less invasive testing and the simultaneous mapping of several biomarkers of genomic alterations in the tumor.
On the basis of end user, the the genomics in cancer care market is classified into hospitals, government institutions and research facilities.
The hospitals segment are expected to dominate the genomics in cancer care market during the forecast period
Hospitals dominated genomics in the cancer care market. The factors, including well-resourced operating & diagnostic rooms, higher purchasing power, the existence of highly skilled healthcare professionals, and improved health coverage for hospital-based healthcare services from several private and group insurance plans, among others, are responsible for the high market share of hospitals.
North America region holds the largest market share in the global Genomics in Cancer Care Market
North America region dominates the global genomics in cancer care market estimated for the largest market share in 2020, owing to the higher percentage rates of cancer disease and the initiatives taken by the government and other institutions related to genomics cancer. As per the Globocan 2020 report, an expected 2,281,658 new cancer cases were diagnosed in the U.S. in 2020, with nearly 612,390 deaths. In 2020, the most frequent cancers were prostate (209,512), and colon (101,809), breast (253,465), lung (227,875) in the U.S.
Also, several government bodies, like National Human Genome Research Institute, have been supporting research associated with human genome sequencing while financing research related to the genome's structure, purpose, and role in health and disease. Moreover, these organizations promote studies on the legal, ethical, and social implications of genome research.
Thus, owing to the growing burden of cancers in the country and increasing research activities about genomics, the market is anticipated to witness significant growth in the North American region.
On the other hand, Asia-Pacific is expected to exhibit the fastest growth rate over the forecast period due to increased healthcare expenditure, rising awareness about early diagnosis, high unmet clinical needs of patients, and effective treatment in emerging countries, such as China and India.
The genomics in cancer care market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Illumina, Inc, Affymetrix, Agilent Technologies, Roche Diagnostics, Cancer Genetics Inc., Beckman Coulter Inc., Bio-Rad Labs, Danaher Corporation, Sigma Aldrich Corporation, and Pacific Bioscience among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the genomics in cancer care market globally.
Overview: Roche Diagnostics is a diagnostic division of Hoffmann-La Roche which manufactures equipment and reagents, for research and medical diagnostic applications. ... Applied Science targets research settings in academia and pharmaceutical and biotechnology industries. Internally, it is organized into five major business areas: Roche Applied Science, Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics and Roche Tissue Diagnostics (Ventana). The main location for Roche Professional Diagnostics is in Rotkreuz, Switzerland.
Product Portfolio: The Company's portfolio comprised of centralised and point of care solutions, custombiotech, diabetes care, molecular diagnostics & research among others.
The global genomics in cancer care market report would provide an access to an approx. 61 market data table, 56 figures and 200 pages.
LIST NOT EXHAUSTIVE